On the Choice of Longitudinal Models for the Analysis of Antitumor Efficacy in Mouse Clinical Trials of Patient-derived Xenograft Models.

Autor: Savel H; Department of Public Health, Inserm Bordeaux Population Health Research Centre, U1219, University of Bordeaux, Bordeaux, France.; Ipsen Innovation, Les Ulis, France.; Inria, SISTM, Talence, France., Barbier S; Ipsen Innovation, Les Ulis, France., Proust-Lima C; Department of Public Health, Inserm Bordeaux Population Health Research Centre, U1219, University of Bordeaux, Bordeaux, France.; University of Bordeaux, INSERM, CHU de Bordeaux, Institut Bergonié, CIC-EC 1401, Bordeaux, France., Rondeau V; Department of Public Health, Inserm Bordeaux Population Health Research Centre, U1219, University of Bordeaux, Bordeaux, France., Thiébaut R; Department of Public Health, Inserm Bordeaux Population Health Research Centre, U1219, University of Bordeaux, Bordeaux, France.; Inria, SISTM, Talence, France.; University of Bordeaux, INSERM, CHU de Bordeaux, Institut Bergonié, CIC-EC 1401, Bordeaux, France., Meyer-Losic F; Ipsen Innovation, Les Ulis, France., Richert L; Department of Public Health, Inserm Bordeaux Population Health Research Centre, U1219, University of Bordeaux, Bordeaux, France.; Inria, SISTM, Talence, France.; University of Bordeaux, INSERM, CHU de Bordeaux, Institut Bergonié, CIC-EC 1401, Bordeaux, France.

Publikováno v: Cancer research communications [Cancer Res Commun] 2023 Jan 26; Vol. 3 (1), pp. 140-147. Date of Electronic Publication: 2023 Jan 26 (Print Publication: 2023).

Incidence of cytomegalovirus infection in seropositive kidney transplant recipients treated with everolimus: A randomized, open-label, multicenter phase 4 trial.

Autor: Kaminski H; Department of Nephrology, Transplantation, Dialysis and Apheresis, CHU Bordeaux, Bordeaux, France.; UMR 5164-ImmunoConcEpT, University of Bordeaux, CNRS, Bordeaux University, Bordeaux, France., Kamar N; Department of Nephrology and Organ Transplantation, CHU Toulouse, Toulouse, France.; INSERM U1043, IFR-BMT, Toulouse, France., Thaunat O; Department of Nephrology, Transplantation and Clinical Immunology of Edouard Herriot Hospital, Hospices Civils de Lyon, Lyon-I University UFR Lyon Est, Lyon, France., Bouvier N; Department of Nephrology, Transplantation, Dialysis, CHU Caen, Caen, France., Caillard S; Department of Nephrology and Transplantation, CHU Strasbourg, Strasbourg, France., Garrigue I; Laboratory of Virology, CHU Bordeaux, Bordeaux, France., Anglicheau D; Department of Nephrology and Kidney Transplantation, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France., Rérolle JP; Department of Nephrology and Transplantation, CHU Limoges, Limoges, France., Le Meur Y; Department of Nephrology and Transplantation, Brest University Hospital, Brest, France., Durrbach A; Department of Nephrology and Kidney Transplantation, INSERM 1186, Henri Mondor Hospital, Assistance Publique-Hôpitaux de Paris, Paris Saclay University, Paris, France., Bachelet T; Department of Nephrology, Transplantation, Dialysis and Apheresis, CHU Bordeaux, Bordeaux, France., Savel H; CHU Bordeaux, Service d'information médicale, Bordeaux, France., Coueron R; CHU Bordeaux, Service d'information médicale, Bordeaux, France., Visentin J; UMR 5164-ImmunoConcEpT, University of Bordeaux, CNRS, Bordeaux University, Bordeaux, France.; Laboratory of Immunology and Immunogenetics, CHU Bordeaux, Bordeaux, France., Del Bello A; Department of Nephrology and Organ Transplantation, CHU Toulouse, Toulouse, France.; INSERM U1043, IFR-BMT, Toulouse, France., Pellegrin I; UMR 5164-ImmunoConcEpT, University of Bordeaux, CNRS, Bordeaux University, Bordeaux, France.; Laboratory of Immunology and Immunogenetics, CHU Bordeaux, Bordeaux, France., Déchanet-Merville J; UMR 5164-ImmunoConcEpT, University of Bordeaux, CNRS, Bordeaux University, Bordeaux, France., Merville P; Department of Nephrology, Transplantation, Dialysis and Apheresis, CHU Bordeaux, Bordeaux, France.; UMR 5164-ImmunoConcEpT, University of Bordeaux, CNRS, Bordeaux University, Bordeaux, France., Thiébaut R; CHU Bordeaux, Service d'information médicale, Bordeaux, France.; INSERM U1219 Bordeaux Population Health Research Center, Inria SISTM, Bordeaux University, Bordeaux, France., Couzi L; Department of Nephrology, Transplantation, Dialysis and Apheresis, CHU Bordeaux, Bordeaux, France.; UMR 5164-ImmunoConcEpT, University of Bordeaux, CNRS, Bordeaux University, Bordeaux, France.

Publikováno v: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons [Am J Transplant] 2022 May; Vol. 22 (5), pp. 1430-1441. Date of Electronic Publication: 2022 Jan 19.

Prospective Evaluation of the First Option, Second-Line Therapy in Childhood Chronic Immune Thrombocytopenia: Splenectomy or Immunomodulation.

Autor: Ducassou S; Pediatric Hematology Unit, CIC1401, INSERM CICP, University Hospital of Bordeaux, Bordeaux, France; Centre de Référence National des Cytopénies Autoimmunes de l'Enfant (CEREVANCE), University Hospital of Bordeaux, Bordeaux, France., Fernandes H; Centre de Référence National des Cytopénies Autoimmunes de l'Enfant (CEREVANCE), University Hospital of Bordeaux, Bordeaux, France., Savel H; Unité de Soutien Méthodologique à la Recherche Clinique (USMR) University Hospital of Bordeaux, Bordeaux, France., Bertrand Y; Pediatric Hematology Unit, Institute of Pediatric Hematology and Oncology, Claude Bernard University Lyon, Lyon, France., Leblanc T; Department of Hematology, APHP - Hopital Robert Debré, Centre de Ré́férence National des Cytopénies Autoimmunes de l'Enfant (CEREVANCE), Paris, France., Abou Chahla W; Department of pediatric Hematology, University Hospital of Lille, Lille, France., Pasquet M; Department of pediatric Hematology, University Hospital of Toulouse, Toulouse, France., Leverger G; Sorbonne Université, INSERM, Centre de Recherche Saint Antoine, AP-HP, Hôpital Armand Trousseau, Service d'Hématologie Oncologie Pédiatrique, Centre de Référence National des Cytopénies Autoimmunes de lEnfant (CEREVANCE), Paris, France., Barlogis V; Department of Pediatric Hematology AP-HM Hôpital Timone Enfant, Marseille, France., Thomas C; Department of Pediatric Hematology and Oncology, University Hospital of Nantes, Nantes, France., Bayart S; Department of Pediatric Hematology, University Hospital of Rennes, Rennes, France., Pellier I; Department of Pediatric Hematology and Oncology, University Hospital of Angers, Angers, France., Armari-Alla C; Department of Pediatric Hematology, University Hospital of Grenoble, Grenoble, France., Guitton C; Department of Pediatrics, University Hospital of Bicêtre, Le Kremlin-Bicêtre, France., Cheikh N; Department of Pediatric Hematology and Oncology, University Hospital of Besançon, Besançon, France., Kherfellah D; Centre de Référence National des Cytopénies Autoimmunes de l'Enfant (CEREVANCE), University Hospital of Bordeaux, Bordeaux, France., Vassal G; Gustave Roussy Cancer Center, Clinical Research Direction, Paris-Saclay University, Villejuif, France., Thiébaut R; Unité de Soutien Méthodologique à la Recherche Clinique (USMR) University Hospital of Bordeaux, Bordeaux, France., Laghouati S; Gustave Roussy Cancer Center, Pharmacovigilance Unit, Paris-Saclay University, Villejuif, France., Aladjidi N; Pediatric Hematology Unit, CIC1401, INSERM CICP, University Hospital of Bordeaux, Bordeaux, France; Centre de Référence National des Cytopénies Autoimmunes de l'Enfant (CEREVANCE), University Hospital of Bordeaux, Bordeaux, France. Electronic address: nathalie.aladjidi@chu-bordeaux.fr.

Publikováno v: The Journal of pediatrics [J Pediatr] 2021 Apr; Vol. 231, pp. 223-230. Date of Electronic Publication: 2020 Dec 17.

ASSESSMENT OF EARLY CHANGES IN SPECTRAL DOMAIN-OPTICAL COHERENCE TOMOGRAPHY AFTER INITIATION OF TREATMENT WITH INTRAVITREAL AFLIBERCEPT (EYLEA) OVER A 12-WEEK PERIOD FOR PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Multicenter French Study (START).

Autor: Korobelnik JF; Service D'Ophtalmologie, Hôpital Pellegrin, CHU de Bordeaux, Bordeaux, France.; Université de Bordeaux, Inserm, Bordeaux Population Health Research Center, Leha team, UMR 1219, Bordeaux, France., Souied EH; Department of Ophthalmology, Hôpital Intercommunal de Créteil, University Paris Est, Créteil, France., Oubraham H; Department of Ophthalmology, Hôpital Intercommunal de Créteil, University Paris Est, Créteil, France., Razavi S; Centre Ophtalmologique Transparence Tours, Tours, France., Mauget-Faÿsse M; Centre D'Investigation Clinique, Rothschild Foundation, Paris, France., Savel H; CHU de Bordeaux, Pôle de santé publique, Unité de soutien méthodologique à la recherche clinique et épidémiologique and CIC 1401-EC, Bordeaux, France ; and., Chene G; CHU de Bordeaux, Pôle de santé publique, Unité de soutien méthodologique à la recherche clinique et épidémiologique and CIC 1401-EC, Bordeaux, France ; and., Wolf S; Department of Ophthalmology, Inselspital, University Hospital and University of Bern, Bern, Switzerland.

Publikováno v: Retina (Philadelphia, Pa.) [Retina] 2021 Mar 01; Vol. 41 (3), pp. 588-594.

Calcul du nombre de sujets nécessaire dans le contexte d’analyse du microbiome

Autor: Coueron, R., Savel, H., Hejblum, B.P.

Publikováno v: In Revue d'Epidemiologie et de Santé Publique May 2019 67 Supplement 3:S135-S136